Tela Bio Inc (TELA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tela Bio Inc (TELA) has a cash flow conversion efficiency ratio of 2.148x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.17 Million) by net assets ($-5.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tela Bio Inc balance sheet independence to measure how much of total assets are equity-financed.
Tela Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Tela Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore TELA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Tela Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tela Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
P3 Health Partners Inc
NASDAQ:PIII
|
0.206x |
|
Globon Co. Ltd
KQ:019660
|
-0.073x |
|
Nath Bio-Genes (India) Limited
NSE:NATHBIOGEN
|
-0.160x |
|
Globus Maritime Ltd
NASDAQ:GLBS
|
0.020x |
|
Kekrops S.A.
AT:KEKR
|
-0.005x |
|
Beauty Community Public Company Limited
BK:BEAUTY
|
0.033x |
|
Ymc Co. Ltd
KQ:155650
|
-0.010x |
|
Stampede Drilling Inc
V:SDI
|
0.070x |
Annual Cash Flow Conversion Efficiency for Tela Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Tela Bio Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see TELA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-28.22 Million | -4.470x | -205.82% |
| 2024-12-31 | $28.46 Million | $-41.59 Million | -1.462x | +32.45% |
| 2023-12-31 | $18.88 Million | $-40.86 Million | -2.164x | +24.03% |
| 2022-12-31 | $14.30 Million | $-40.75 Million | -2.849x | -88.12% |
| 2021-12-31 | $20.10 Million | $-30.43 Million | -1.514x | -203.54% |
| 2020-12-31 | $49.03 Million | $-24.46 Million | -0.499x | +39.49% |
| 2019-12-31 | $30.96 Million | $-25.52 Million | -0.824x | -670.38% |
| 2018-12-31 | $-137.86 Million | $-19.92 Million | 0.145x | -4.49% |
| 2017-12-31 | $-108.17 Million | $-16.37 Million | 0.151x | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more